Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study.

ABSTRACT:

Objectives

To develop a pragmatic twice daily lamivudine dosing strategy for preterm infants from 24 to 37 completed weeks of gestation.

Methods

Data were combined from eight pharmacokinetic studies in neonates and infants receiving lamivudine oral solution. A population pharmacokinetic model was developed using non-linear mixed effects regression. Different lamivudine dosing strategies, stratified by gestational age at birth (GA) bands, were simulated in a virtual population of preterm infants, aimed at maintaining lamivudine drug exposures (AUC0-12) within a reference target range of 2.95 to 13.25 µg·h/mL, prior to switching to WHO-weight band doses when ≥4 weeks of age and weighing ≥3 kg.

Results

A total of 154 infants (59% female) contributed 858 lamivudine plasma

SUBMITTER: Bekker A 

PROVIDER: S-EPMC11441998 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature